Antiplatelet therapy
Copyright policy )Antiplatelet therapy
Within the last few years antiplatelet therapy has developed exponentially, with new agents being tested in an increasing number of clinical scenarios. The mechanism of action of these newer agents and evidence of benefit is prevented in this review.
Aspirin, Platelet Aggregation, Abciximab, Antibodies, Monoclonal, Coronary Disease, Thrombosis, Platelet Glycoprotein GPIIb-IIIa Complex, Platelet Activation, Immunoglobulin Fab Fragments, Purinergic P2 Receptor Antagonists, Humans, Receptors, Thrombin, Platelet Aggregation Inhibitors
Aspirin, Platelet Aggregation, Abciximab, Antibodies, Monoclonal, Coronary Disease, Thrombosis, Platelet Glycoprotein GPIIb-IIIa Complex, Platelet Activation, Immunoglobulin Fab Fragments, Purinergic P2 Receptor Antagonists, Humans, Receptors, Thrombin, Platelet Aggregation Inhibitors
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).7 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!